NASDAQ:NOVN Novan Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Novan Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.53 +0.01 (+1.91 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$0.52Now: $0.53▼$0.5650-Day Range$0.38MA: $0.53▼$0.6852-Week Range$0.22Now: $0.53▼$3.72Volume6.12 million shsAverage Volume15.76 million shsMarket Capitalization$73.35 millionP/E RatioN/ADividend YieldN/ABeta-0.26 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. has a strategic alliance with Orion Corporation to manufacture topical nitric oxide-releasing product candidates. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingNovan has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.00, Novan has a forecasted upside of 87.4% from its current price of $0.53.Amount of Analyst CoverageNovan has received no research coverage in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesNovan has received 219 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNovan has received 276 “underperform” votes. (Add your “underperform” vote.)Community SentimentNovan has received 55.76% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Novan and other stocks. Vote “Outperform” if you believe NOVN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNovan does not currently pay a dividend.Dividend GrowthNovan does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Novan insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Novan is held by insiders.Percentage Held by InstitutionsOnly 2.97% of the stock of Novan is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Novan are expected to grow in the coming year, from ($0.30) to ($0.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novan is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Novan is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.22 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NOVN Previous Symbol CUSIPN/A CIK1467154 Webwww.novan.com Phone919-485-8080Debt Debt-to-Equity RatioN/A Current Ratio3.98 Quick Ratio3.98Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.90 million Price / Sales14.97 Cash FlowN/A Price / Cash FlowN/A Book Value($0.89) per share Price / Book-0.60Profitability EPS (Most Recent Fiscal Year)($0.80) Net Income$-30,640,000.00 Net Margins-378.10% Return on EquityN/A Return on Assets-46.52%Miscellaneous Employees47 Outstanding Shares137,468,000Market Cap$73.35 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $0.53 +0.01 (+1.91 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NOVN News and Ratings via Email Sign-up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter. Novan (NASDAQ:NOVN) Frequently Asked Questions How has Novan's stock price been impacted by COVID-19 (Coronavirus)? Novan's stock was trading at $0.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NOVN shares have increased by 2.6% and is now trading at $0.5336. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Novan? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novan in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Novan. When is Novan's next earnings date? Novan is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Novan. How were Novan's earnings last quarter? Novan Inc (NASDAQ:NOVN) announced its quarterly earnings data on Friday, August, 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.03. The company earned $1.32 million during the quarter, compared to analyst estimates of $1.09 million. View Novan's earnings history. What price target have analysts set for NOVN? 2 brokerages have issued twelve-month target prices for Novan's stock. Their forecasts range from $0.50 to $1.50. On average, they expect Novan's share price to reach $1.00 in the next twelve months. This suggests a possible upside of 87.4% from the stock's current price. View analysts' price targets for Novan. Are investors shorting Novan? Novan saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 4,050,000 shares, an increase of 43.6% from the July 15th total of 2,820,000 shares. Based on an average trading volume of 28,720,000 shares, the short-interest ratio is currently 0.1 days. View Novan's Short Interest. Who are some of Novan's key competitors? Some companies that are related to Novan include Affimed (AFMD), Aldeyra Therapeutics (ALDX), Cyclerion Therapeutics (CYCN), Liminal BioSciences (LMNL), Osmotica Pharmaceuticals (OSMT), Neptune Wellness Solutions (NEPT), Selecta Biosciences (SELB), Immunic (IMUX), ProQR Therapeutics (PRQR), Calithera Biosciences (CALA), NextCure (NXTC), Arbutus Biopharma (ABUS), Lannett (LCI), MediciNova (MNOV) and Tiziana Life Sciences (TLSA). View all competitors. What other stocks do shareholders of Novan own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novan investors own include Gran Tierra Energy (GTE), BioNano Genomics (BNGO), Pennsylvania R.E.I.T. (PEI), Cannabics Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), AEterna Zentaris (AEZS), CBL & Associates Properties (CBL) and OrganiGram (OGI). Who are Novan's key executives? Novan's management team includes the following people: Mr. G. Kelly Martin, CEO & Director (Age 60)Ms. Paula Brown Stafford, Pres, COO & Director (Age 54)Mr. John M. Gay, VP of Fin., Corp. Controller, Principal Financial Officer and Corp. Sec. (Age 42)Dr. Nathan Stasko, Co-Founder & Chief Scientific Officer (Age 39)Dr. Carri Geer, Sr. VP & CTO When did Novan IPO? (NOVN) raised $46 million in an IPO on Wednesday, September 21st 2016. The company issued 3,800,000 shares at a price of $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Novan's stock symbol? Novan trades on the NASDAQ under the ticker symbol "NOVN." Who are Novan's major shareholders? Novan's stock is owned by a variety of retail and institutional investors. Top institutional investors include Bridgeway Capital Management Inc. (0.34%) and UBS Group AG (0.25%). Company insiders that own Novan stock include G Kelly Martin, John M Gay, John W Palmour, Life Sciences Holdings L Malin, Paula B Stafford and Robert Alexander Ingram. View institutional ownership trends for Novan. Which major investors are buying Novan stock? NOVN stock was purchased by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., and UBS Group AG. Company insiders that have bought Novan stock in the last two years include G Kelly Martin, John M Gay, John W Palmour, Paula B Stafford, and Robert Alexander Ingram. View insider buying and selling activity for Novan. How do I buy shares of Novan? Shares of NOVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Novan's stock price today? One share of NOVN stock can currently be purchased for approximately $0.53. How big of a company is Novan? Novan has a market capitalization of $73.35 million and generates $4.90 million in revenue each year. The company earns $-30,640,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Novan employs 47 workers across the globe. What is Novan's official website? The official website for Novan is www.novan.com. How can I contact Novan? Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company can be reached via phone at 919-485-8080 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
